Results 201 to 210 of about 2,488,526 (298)

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Frailty-stratified effective dose of nalbuphine for postoperative analgesia in elderly patients undergoing laparoscopic gastrointestinal surgery: a modified Dixon-based dose-finding protocol. [PDF]

BMC Geriatr
Wang W, Wei C, Chen S, Wu G, Xu L, Gao X, Du Y, Liu M, Zhang M, Sun Y.   +9 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Ultraviolet and biological effective dose observations at Gale Crater, Mars. [PDF]

Proc Natl Acad Sci U S A
Viúdez-Moreiras D, Zorzano MP, Lemmon MT, Fairén AG, Saiz-Lopez A, Smith MD.   +5 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Determination of the median effective dose of chloroprocaine in labour: preliminary results [PDF]

, 2015
Anssens, Sarah, Coppens, Marc, De Hert, Stefan, Deschepper, Ellen, Wouters, Patrick   +4 more
core   +1 more source

Treatment strategy in stereotactic radiosurgery for trigeminal neuralgia, essential tremor, and coexisting intracranial tumors: The impact of biologically effective dose on clinical outcome. [PDF]

J Appl Clin Med Phys
Sinha S, Goulenko V, Madhugiri VS, Prasad S, Almeida ND, Shekher R, Podgorsak MB, Plunkett RJ, Prasad D.   +8 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Biologically Effective Dose and Dose Rate in Gamma Knife Radiosurgery for Trigeminal Neuralgia: A Systematic Review and Meta-Analysis. [PDF]

Adv Radiat Oncol
Jomy J, Lin KX, Sharma R, Lu R, Kaushal S, Santiago AT, Keilty D, Shultz D, Coolens C, Cusimano MD, Zadeh G, Hodaie M, Kalia SK, Nassiri F, Meng Y, Tsang DS, Yan M.   +16 more
europepmc   +1 more source